Table 1.

Characteristics of patients in the study population

	Number (%)
Total Number of Patients	130
Age, years (median, range)	74 (32–97)
Sex (Male/Female)	71 (54.6)/59 (45.4)
Primary Cancer Site
Lung	31 (23.8)
Colon	26 (20.0)
Pancreas	12 (9.2)
Liver	7 (5.4)
Stomach	7 (5.4)
Esophagus	5 (3.8)
Breast	5 (3.8)
Ovary	4 (3.1)
Uterine	4 (3.1)
Prostate	3 (2.3)
Other	23 (17.7)
Unknown	3 (2.3)
Metastasis (total number)
Liver	54 (41.5)
Lung	52 (40.0)
Bone	40 (30.8)
Brain	14 (10.8)
PPS
≥ 70	20 (15.4)
40–60	74 (56.9)
≤ 30	29 (22.3)
Unknown	7 (5.4)
Survival, days (median, range) n = 109	18 (2–193)
QLQ-C15-PAL (median (Q1, Q3), mean (± SD))
Physical Functioning (n = 125)	33.3 (20.0, 46.7), 37.0 ± 25.1
Emotional Functioning (n = 129)	66.7 (41.7, 83.3), 63.2 ± 28.3
Dyspnea	33.3 (0.0, 66.7), 39.5 ± 34.4
Pain (n = 129)	50.0 (16.7, 66.7), 47.3 ± 34.0
Insomnia	33.3 (0.0, 66.7), 40.0 ± 36.0
Appetite Loss	66.7 (33.3, 100), 57.7 ± 38.4
Constipation (n = 128)	33.3 (0.0, 66.7), 37.0 ± 35.3
Fatigue (n = 129)	66.7 (44.4, 100), 63.8 ± 29.7
Nausea/Vomiting	0.0 (0.0, 16.7), 18.7 ± 29.6
QOL (n = 124)	50.0 (16.7, 50.0), 38.7 ± 27.1
Inflammatory Biomarkers (median, range) n = 126
CRP (mg/dL)	3.9 (<  0.1–32.1)
Alb (g/dL)	2.6 (1.2–3.9)
NLR (n = 122)	7.6 (0.6–187)

Alb albumin, CRP C-reactive protein, NLR neutrophil-lymphocyte ratio, PPS Palliative Performance Scale, QLQ-C15-PAL European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative Care, QOL quality of life

In the QLQ-C15-PAL, patients rated their symptoms using a 4-point scale (1 = not at all, 2 = a little, 3 = quite a bit, 4 = very much) for two functional domains and 7 symptom domains, and a 7-point scale (range: 1 = very poor to 7 = excellent) for overall QOL. All scale scores were linearly transformed, and the resultant scores ranged from 0 to 100. Q1: first quarter (25% quartile), Q3: third quarter (75% quartile), SD: standard deviation